comparemela.com

Latest Breaking News On - Pierre bastid lohas - Page 3 : comparemela.com

CARMAT Announces the Issuance of a Second Tranche of Equity Warrants Within the Framework of Its Contingent Equity Line With Kepler Cheuvreux

(0) Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces the issuance of a second tranche of 650,000 equity warrants within the framework of the contingent equity line with Kepler Cheuvreux. On September 27, 2018, CARMAT put in place a contingent equity line contract with Kepler Cheuvreux for a maximum amount of €25 million for a duration of 3 years. The first tranche of 400,000 equity warrants, issued in September 2018, has, to date, enabled the Company to benefit from €9.1 million in financing within the framework of this contract.

CARMAT Obtains a €1 4 Million Grant as Part of the Industrial Recovery Plan - Strategic Sectors Call for Projects

(2) Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that is has obtained a €1.4 million grant as a winner of the Ministry for Industry s Industrial recovery plan Strategic sectors call for projects. This non-dilutive financing will contribute to the CAP 23 industrialization program that aims to size the production of the Aeson heart for its commercial phase, notably by: increasing CARMAT s production capacity on its Bois-d Arcy industrial site; digitalizing this site; and

CARMAT Announces the Results of Its Capital Increase of €55 7 Million After Exercise of the Increase Option

Provided by Business Wire Mar 8, 2021 9:59 PM UTC CARMAT Announces the Results of Its Capital Increase of €55.7 Million After Exercise of the Increase Option Not for Distribution in the United States of America, Canada, Australia or Japan Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart 1, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure (the “ Company”), today announces the results of its capital increase launched on February 26, 2021 which implemented without shareholders’ preferential subscription rights by way of a public offering and with a priority subscription period, on an irreducible basis ( à titre irréductible) only, to its existing shareholders and a global offering (the “ Offering”), for an amount (including the issue premium) of €55.

CARMAT Announces the Results of Its Capital Increase of €55 7 Million After Exercise of the Increase Option

CARMAT Announces the Results of Its Capital Increase of €55 7 Million After Exercise of the Increase Option
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

CARMAT: Availability of the 2020 Universal Registration Document

CARMAT: Availability of the 2020 Universal Registration Document
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.